ArticlePediatric nephrology (Berlin, Germany)2026
Anti-rituximab antibodies: implications for clinical outcomes and safety in pediatric idiopathic nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Paediatric lupus nephritis: defining remission and the evolving therapeutic landscape.Pediatric nephrology (Berlin, Germany) · 2026Article
- Clinical significance of anti-rituximab antibody status before rituximab administration in children with frequently relapsing or steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab (RTX) has been proven effective in the treatment of idiopathic nephrotic syndrome (INS). The development of anti-rituximab antibodies (ARA) may compromise its efficacy and safety. However, the incidence and clinical relevance of ARA in pediatric INS remain incompletely defined.
methodsThis retrospective study involved 90 pediatric patients with INS who were treated with RTX at a dose of 375 mg/m
resultsARA were detected in 30 of 90 patients (33.3%). The incidence of ARA positivity increased progressively with subsequent RTX infusions, rising markedly after the third infusion. ARA-positive patients had a significantly higher relapse rate compared with ARA-negative patients (83.3% vs. 25.0%, p < 0.001), higher CD20⁺ B-cell counts at 3 and 6 months (p < 0.005), and an increased risk of infusion-related reactions (IRR) during multiple RTX infusions (p = 0.019). Multivariate analyses identified younger age at first RTX administration, a higher number of RTX infusions, and occurrence of multiple IRR as independent risk factors for ARA positivity.
conclusionARA are associated with impaired B-cell depletion and higher relapse rates. Monitoring ARA may help identify patients at risk of treatment failure and guide individualized therapeutic strategies.
Indexed as
Identifiers
42565989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.